Related Experiment Video

Updated: Aug 29, 2026

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies
09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

[Neoangiogenesis: from molecular biology to clinical medicine]

G Odoni1, K Amann, E Ritz

  • 1Istituto di Clinica Medica, Universita' di Heidelberg - Germania.

Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia
|January 21, 2004
PubMed

Insights

Cardiovascular disease is a major concern for patients with end-stage renal disease, often linked to "uraemic cardiomyopathy." Impaired blood vessel formation in the heart contributes to this condition, but therapeutic angiogenesis shows promise for treatment.

Area of Science:

  • Cardiovascular pathology
  • Renal disease research
  • Vascular biology

Context:

  • End-stage renal disease (ESRD) patients face high rates of premature death, primarily from cardiovascular disease.
  • A specific cardiac condition, "uraemic cardiomyopathy," is implicated in ESRD-related mortality.
  • Cardiac changes in uraemia are linked to impaired blood vessel formation.

Purpose:

  • To review the pathogenesis of cardiac changes in uraemia.
  • To elucidate the role of impaired vessel formation in uraemic cardiomyopathy.
  • To explore therapeutic angiogenesis as a potential treatment strategy.

Summary:

  • Patients with end-stage renal disease exhibit significant alterations in myocardial capillarization, including reduced capillary supply and increased intercapillary distance.
  • Experimental and autoptic data confirm these structural cardiac changes in renal failure.
  • Therapeutic angiogenesis, utilizing growth factors like VEGF, offers a promising avenue for treating uraemic cardiomyopathy by promoting new vessel growth.

Impact:

  • Understanding the mechanisms of uraemic cardiomyopathy can lead to targeted therapies.
  • Identifying impaired vascularization as a key factor highlights potential treatment targets.
  • Therapeutic angiogenesis presents a novel approach to managing cardiovascular complications in ESRD.

More Related Videos

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Investigating Angiogenesis on a Functional and Molecular Level by Leveraging the Scratch Wound Migration Assay and the Spheroid Sprouting Assay09:16

Investigating Angiogenesis on a Functional and Molecular Level by Leveraging the Scratch Wound Migration Assay and the Spheroid Sprouting Assay

Published on: May 31, 2024

Related Concept Videos

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...